NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society…
Understanding Differences in ASCVD Risk and Outcomes in South Asians
A greater prevalence of dyslipidemia, insulin resistance, and atherosclerotic cardiovascular disease (ASCVD) and related-mortality are now well-recognized in South Asians living in the U.S. (SAUS),…
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other…
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association
Statins for Primary Prevention in Women: How an Individual-Benefit Model Could Expand Treatment to Hypercholesterolemic Women Under Age 65 with 10-Year ASCVD Risk Less Than 7.5%
Evidence in support of statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) in women was sparse until recently.1 However, meta-analyses have documented that…